Annamalai Senthilkumar, Kamalakaran Arunkumar, Jayaraman Balaji, Selvakumar Anushya, Kulkarni Harish Suresh
Department of Oral and Maxillofacial Surgery, Tamil Nadu Government Dental College and Hospital, Chennai, India.
Arch Craniofac Surg. 2025 Apr;26(2):70-75. doi: 10.7181/acfs.2024.0091. Epub 2025 Apr 20.
Medication-related osteonecrosis of the jaw (MRONJ) is a relatively rare but well-documented complication of bisphosphonate therapy. Bisphosphonates are prescribed to millions of patients for the treatment of osteoporosis, Paget's disease, multiple myeloma, bone metastases, and other bone-related conditions. These drugs inhibit bone resorption by binding to hydroxyapatite, particularly in areas of active resorption, thereby preventing osteoclasts from attaching to the bone. Long-term bisphosphonate therapy is considered a primary risk factor for MRONJ. Bisphosphonate-induced osteonecrosis typically manifests as exposed alveolar bone, which may occur spontaneously or following invasive dental procedures such as extractions, apicectomies, or implant placement. This case report describes a female who developed osteonecrosis in the maxilla and mandible after undergoing bisphosphonate therapy for multiple myeloma and subsequent tooth extractions.
药物相关性颌骨坏死(MRONJ)是双膦酸盐治疗一种相对罕见但有充分文献记载的并发症。数百万患者因治疗骨质疏松症、佩吉特病、多发性骨髓瘤、骨转移及其他与骨相关疾病而服用双膦酸盐。这些药物通过与羟基磷灰石结合抑制骨吸收,尤其是在活跃吸收区域,从而阻止破骨细胞附着于骨。长期双膦酸盐治疗被认为是MRONJ的主要危险因素。双膦酸盐诱导的骨坏死通常表现为暴露的牙槽骨,可自发出现或在拔牙、根尖切除术或种植体植入等侵入性牙科手术后发生。本病例报告描述了一名女性,在接受双膦酸盐治疗多发性骨髓瘤及随后拔牙后,上颌骨和下颌骨发生了骨坏死。